Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.53 |
| ▸ | MTOR | P42345 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26337500 | 0.83 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDPIK3R1PIK3CA | |
| SCHEMBL15207184 | 0.80 | ALDH1A1 (0.56) | ALDH1A1KDM4EHPGDPIK3R1PIK3CA | |
| SCHEMBL1707833 | 0.80 | ALDH1A1 (0.56) | ALDH1A1KDM4EHPGDPIK3R1PIK3CA | |
| SCHEMBL8607492 | 0.79 | KDM4E (0.57) | ALDH1A1KDM4EHPGDPIK3R1PIK3CA | |
| SCHEMBL8973821 | 0.78 | HTT (0.63) | ALDH1A1KDM4EHPGDPIK3R1PIK3CA | |
| SCHEMBL26037956 | 0.78 | HRH4 (0.61) | KMT2AHRH4 | |
| SCHEMBL19105591 | 0.77 | KMT2A (0.53) | ALDH1A1KDM4EHPGDPIK3R1PIK3CA | |
| SCHEMBL17309194 | 0.77 | HRH4 (0.66) | ALDH1A1KDM4EHPGDPIK3R1PIK3CA | |
| SCHEMBL12110268 | 0.77 | KMT2A (0.56) | ALDH1A1KDM4EHPGDPIK3CAKMT2A | |
| SCHEMBL1443593 | 0.77 | PIK3CA (0.61) | ALDH1A1KDM4EHPGDPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | claimed |
| CN-101790374-A | Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted | LUNDBECK & CO AS H | 2010-07-28 | — | — | CN | claimed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| US-7683058-B2 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2010-03-23 | — | — | US | claimed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | claimed |
| EP-1937653-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H.Lundbeck A/S (DK) | 2008-07-02 | — | — | EP | claimed |
| WO-2007065449-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H. LUNDBECK A/S (DK) | 2007-06-14 | — | — | WO | claimed |
| US-20070066612-A1 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| CN-101378742-B | Use of KCNQ-openers for the preparation of a pharmaceutical composition for the treatment of schizophrenia | LUNDBECK & CO AS H | 2013-07-10 | — | — | CN | disclosed |
| EP-2554162-A1 | Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia | H. Lundbeck A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | disclosed |
| EP-1937653-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H.Lundbeck A/S (DK) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007065449-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H. LUNDBECK A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065449-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H. LUNDBECK A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
| US-20070066612-A1 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | disclosed |
| US-20070066612-A1 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | disclosed |
| US-20070066612-A1 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066612-A1 | Substituted pyrimidine derivatives | DPYD, TYMP, TYMS | ALDH1A1 641/4885KDM4E 3998/4885HPGD 767/4885 |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | KCNQ2, KCNQ4, KCNQ1 | ALDH1A1 1575/4885KDM4E 950/4885HPGD 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.